Notably, 10.8% of patients who received Enhertu experienced ILD compared to 2.5% of patients receiving Kadcyla, and this led to an increase in drug discontinuation for Enhertu, which was 17.9% ...
Destiny: Rising season 2 launches on Nov. 11, lasting until Jan. 1, and debuts the new mythic character Maru, the starbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback